MedTrace Logo

Induction and Maintenance of Remission With Pentasa as Ulcerative Colitis Treatment

NCT02261636 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2022-05-20

No results posted yet for this study

Summary

For both induction of remission and in maintenance of remission, different doses and treatment durations are used in practice. The aim of this study is to assess how mesalazine is used in clinical practice, at which doses and for how long and how these differences impact the patient disease state and work productivity.

Conditions

Interventions

DRUG

mesalazine

Sponsors & Collaborators

  • Ferring Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Global Clinical Compliance · Ferring Pharmaceuticals

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2019-01-14
Completion
2019-01-14

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02261636 on ClinicalTrials.gov